
Sir Andrew Witty, chief executive of GSK, declined to give any details on what impact the review would have on staff numbers – insisting it could mean the business hires more people in Europe – but analysts raised fears that the move signalled “downsizing”.
http://www.telegraph.co.uk/finance/jobs/9646589/GSK-to-review-European-operations-amid-sales-fall.html